SCHEMBL1932255

SCHEMBL1932255

ClCc1cc(OCc2ccccc2)ccn1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX5 P09917 1/20 0.50
MEN1 O00255 1/20 0.49
ALDH1A1 P00352 1/20 0.49
KMT2A Q03164 1/20 0.49
CYP3A4 P08684 1/20 0.49
MAOB P27338 7/20 0.47
LNPEP Q9UIQ6 1/20 0.47
MAOA P21397 3/20 0.46
CYP4F2 P78329 1/20 0.45
CYP4A11 Q02928 1/20 0.45
BCHE P06276 1/20 0.45
LMNA P02545 1/20 0.44
CYP1A2 P05177 1/20 0.44
PTGS1 P23219 1/20 0.44
SLC6A2 P23975 1/20 0.44
CYP2C19 P33261 1/20 0.44
PTGS2 P35354 1/20 0.44
SLC6A3 Q01959 1/20 0.44
HIF1A Q16665 1/20 0.44
HDAC6 Q9UBN7 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL18686893 0.98 MEN1 (0.51) ALOX5MEN1ALDH1A1KMT2ACYP3A4
SCHEMBL29992952 0.83 CYP4F2 (0.53) ALOX5MEN1ALDH1A1KMT2ACYP3A4
SCHEMBL1932252 0.83 CYP4F2 (0.53) ALOX5MEN1ALDH1A1KMT2ACYP3A4
SCHEMBL1931475 0.83 MAOB (0.53) ALOX5MEN1ALDH1A1KMT2ACYP3A4
SCHEMBL30931669 0.83 MAOB (0.53) ALOX5MEN1ALDH1A1KMT2ACYP3A4
SCHEMBL15877638 0.83 ALOX5 (0.53) ALOX5MEN1KMT2ACYP3A4MAOB
SCHEMBL9370232 0.80 MAOB (0.50) MAOBMAOA
SCHEMBL19859717 0.80 LNPEP (0.56) ALOX5MEN1ALDH1A1KMT2ACYP3A4
SCHEMBL15779670 0.79 MAOB (0.59) ALOX5CYP3A4MAOBMAOACYP4F2
SCHEMBL190551 0.79 ALOX5 (0.53) ALOX5CYP3A4MAOBMAOACYP4F2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10975091-B2 Pyridine derivative ASTELLAS PHARMA INC. (JP) 2021-04-13 US disclosed
EP-3150581-B1 PYRIDINE DERIVATIVE ASTELLAS PHARMA INC (JP) 2020-04-15 EP disclosed
US-20200055868-A1 PYRIDINE DERIVATIVE ASTELLAS PHARMA INC. (JP) 2020-02-20 US disclosed
US-10421762-B2 Pyridine derivative ASTELLAS PHARMA INC. (JP) 2019-09-24 US disclosed
US-20170190715-A1 PYRIDINE DERIVATIVE ASTELLAS PHARMA INC. (JP) 2017-07-06 US disclosed
US-20170190715-A1 PYRIDINE DERIVATIVE ASTELLAS PHARMA INC. (JP) 2017-07-06 US disclosed
EP-3150581-A1 PYRIDINE DERIVATIVE Astellas Pharma Inc. (JP) 2017-04-05 EP disclosed
WO-2015182686-A1 PYRIDINE DERIVATIVE アステラス製薬株式会社 2015-12-03 WO disclosed
US-8633216-B2 Imidazo[1,5-a]pyridine derivatives, method for preparing same and pharmaceutical compositions containing same SANOFI (FR) 2014-01-21 US disclosed
EP-1861403-B1 NOVEL IMIDAZO[1,5-A]PYRIDINE DERIVATIVES, METHOD FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME SANOFI SA (FR) 2012-05-02 EP disclosed
US-8008321-B2 Imidazo[1,5-a]pyridin-3-yl)(3-methoxy-4-nitrophenyl)methanone; a and b fibroblast growth factor receptors (FGFR) antagonist; anticarcinogenic, antitumor: lung, breast, prostate, melanomas, gliomas; antiinflammatory, vascular smooth muscle cells: atherosclerosis, restenosis, stent and bypass complications SANOFI-AVENTIS (FR) 2011-08-30 US disclosed
US-20110136856-A1 Novel imidazo[1,5-a]pyridine derivatives, method for preparing same and pharmaceutical compositions containing same SANOFI-AVENTIS (FR) 2011-06-09 US disclosed
CN-102050821-A Novel imidazo [1,5-a ] pyridine derivatives, process for their preparation and pharmaceutical compositions containing them SANOFI AVENTIS 2011-05-11 CN disclosed
US-20080108648-A1 Novel imidazo[1,5-a] pyridine derivatives, method for preparing same and pharmaceutical compositions containing same SANOFI-AVENTIS (FR) 2008-05-08 US disclosed
CN-101160309-A Novel imidazo [1, 5-a ] pyridine derivatives, process for their preparation and pharmaceutical compositions containing them SANOFI AVENTIS (FR) 2008-04-09 CN disclosed
EP-1861403-A1 NOVEL IMIDAZO[1,5-A]PYRIDINE DERIVATIVES, METHOD FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME Sanofi-Aventis (FR) 2007-12-05 EP disclosed
WO-2006097625-A1 NOVEL IMIDAZO[1,5-A]PYRIDINE DERIVATIVES, METHOD FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME SANOFI-AVENTIS (FR) 2006-09-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080108648-A1 Novel imidazo[1,5-a] pyridine derivatives, method for preparing same and pharmaceutical compositions containing same CYP3A5, CYP4B1, CYP3A7 ALOX5 1219/4885MEN1 919/4885ALDH1A1 238/4885
US-20200055868-A1 PYRIDINE DERIVATIVE LAP3, PREP, DNPEP ALOX5 204/4885MEN1 3189/4885ALDH1A1 360/4885
US-20110136856-A1 Novel imidazo[1,5-a]pyridine derivatives, method for preparing same and pharmaceutical compositions containing same P2RX6, IL5, ATIC ALOX5 1562/4885MEN1 1729/4885ALDH1A1 711/4885
US-10975091-B2 Pyridine derivative LAP3, PREP, DNPEP ALOX5 204/4885MEN1 3189/4885ALDH1A1 360/4885
US-10421762-B2 Pyridine derivative LAP3, PREP, DNPEP ALOX5 204/4885MEN1 3189/4885ALDH1A1 360/4885
US-20170190715-A1 PYRIDINE DERIVATIVE LAP3, PREP, DNPEP ALOX5 204/4885MEN1 3189/4885ALDH1A1 360/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.